Testosterone Enanthate Plateau & Non-Response Troubleshooting

At a glance

• Labeled dose / 50 to 400 mg intramuscularly every 2 to 4 weeks [1]
• Monthly upper range / total doses above 400 mg per month are not required [1]
• Injection frequency / more often than every 2 weeks rarely indicated [1]
• Diagnosis check / morning serum testosterone below normal on at least two separate days [1]
• Main monitoring and warning topics / blood pressure, hematocrit, venous thromboembolism symptoms, gynecomastia [1]
• Guideline monitoring / symptoms, serum testosterone, hematocrit, prostate cancer risk in first year [2]

What the enanthate label actually says

The enanthate label gives 50 to 400 mg every 2 to 4 weeks for male hypogonadism. It states that total doses above 400 mg per month are not required because of the prolonged action of the preparation, and that injections more frequently than every 2 weeks are rarely indicated [1].

Check the diagnosis before blaming the ester

The label says to confirm hypogonadism by measuring serum testosterone in the morning on at least two separate days and finding both values below the normal range [1]. The Endocrine Society guideline makes the same point: diagnose only in men with symptoms and signs plus unequivocally and consistently low serum testosterone, use an accurate and reliable assay, and confirm with a repeat morning fasting total testosterone [2]. A single borderline result does not meet the guideline's requirement for unequivocally and consistently low testosterone with compatible symptoms [2].

The label also says safety and efficacy of testosterone enanthate in men with age-related hypogonadism have not been established [1].

What to check when symptoms persist

Free testosterone and SHBG. The Endocrine Society guideline addresses men whose total testosterone is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin [2].

Estradiol and gynecomastia. The label lists gynecomastia and says it frequently develops and occasionally persists [1]. The mechanism is excess estrogen action relative to androgen action in breast tissue [3]; aromatase converts androgens to estrogens [4].

Hematocrit. The label lists polycythemia as an adverse reaction [1]. A meta-analysis of 29 placebo-controlled trials in 3,393 men found intramuscular enanthate/cypionate raised mean hematocrit by 4.0% versus placebo (95% CI 2.9 to 5.1) [5]. The guideline recommends monitoring hematocrit in the first year [2].

Blood pressure and VTE. The label warns that testosterone can increase blood pressure and says products are not recommended in uncontrolled hypertension [1]. It also warns about venous thromboembolism and says to discontinue treatment if VTE is suspected [1]. FDA's class-wide review found that ambulatory blood pressure studies confirmed a blood pressure increase with all testosterone products [6].

Evidence limits

The T-Trials tested testosterone gel for 1 year in 790 men aged 65 or older, not enanthate injections [7].

Frequently asked questions

›What is the labeled dose of testosterone enanthate?

For male hypogonadism, the enanthate label gives 50 to 400 mg intramuscularly every 2 to 4 weeks. It states total doses above 400 mg per month are not required and injections more often than every 2 weeks are rarely indicated [1].

›How do I know if testosterone enanthate is not working?

The label says hypogonadism is confirmed with morning serum testosterone below the normal range on at least two separate days before treatment begins [1], and the Endocrine Society guideline recommends repeating morning fasting total testosterone to confirm the diagnosis [2].

›How does estradiol relate to testosterone enanthate side effects?

Aromatase converts androgens to estrogens [4]. Gynecomastia results from excess estrogen action relative to androgen action in breast tissue [3], and the enanthate label says gynecomastia frequently develops and occasionally persists [1].

›Can testosterone enanthate be injected more often than every 2 weeks?

The label states injections more frequently than every 2 weeks are rarely indicated and total doses above 400 mg per month are not required [1].

References

1. U.S. National Library of Medicine, DailyMed. Testosterone enanthate injection USP intramuscular, Hikma prescribing information. Testosterone enanthate injection USP intramuscular, Hikma label
2. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
3. Narula HS, Carlson HE. Gynaecomastia--pathophysiology, diagnosis and treatment. Nat Rev Endocrinol. 2014;10(11):684-98. Gynaecomastia--pathophysiology, diagnosis and treatment
4. Cooke PS, Nanjappa MK, Ko C, Prins GS, Hess RA. Estrogens in Male Physiology. Physiol Rev. 2017;97(3):995-1043. Estrogens in Male Physiology
5. Nackeeran S, Kohn T, Gonzalez D, White J, Ory J, Ramasamy R. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials. J Urol. 2022;207(1):44-51. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials
6. FDA issues class-wide labeling changes for testosterone products | FDA. FDA issues class-wide labeling changes for testosterone products | FDA
7. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-24. Effects of Testosterone Treatment in Older Men